SEC Filing Document

Company: BIOVENTRIX, INC.
Ticker: 
CIK: 1283259
Filing Type: S-1
Document Type: EX-10.8
Date Filed: 2026-02-12
Accession Number: 0001493152-26-006407
Exchange: 
SIC Code: 3841
SIC Description: Surgical & Medical Instruments & Apparatus
URL: https://www.sec.gov/Archives/edgar/data/1283259/000149315226006407/ex10-8.htm

Chunk 7 of 14
Word Count: 1148
Character Count: 7358

Document Content:

an unaudited balance sheet and statement of stockholders’ equity as of the end of such month, all prepared in accordance with GAAP (except that such financial statements may (i) be subject to normal year-end audit adjustments and (ii) not contain all notes thereto that may be required in accordance with GAAP); soon as practicable, but in any event thirty (30) days before the end of each fiscal year, a budget and business plan for the next fiscal year, prepared on a monthly basis, including balance sheets, income statements, and statements of cash flow for such months and, promptly after prepared, any other budgets or revised budgets prepared by the Company (such budget and business plan that is approved by the Board of Directors (including the vote of at least one (1) of the Preferred Directors then seated, the “Requisite Preferred Director Vote”) is collectively referred to herein as the “Budget”);

(f) with
respect to the financial statements called for in Section 3.1(a), Section 3.1(b) and Section 3.1(d), an instrument
executed by the chief financial officer and chief executive officer of the Company certifying that such financial statements were prepared
in accordance with GAAP consistently applied with prior practice for earlier periods (except as otherwise set forth in Section 3.1(b)
and Section 3.1(d)) and fairly present the financial condition of the Company and its results of operation for the periods specified
therein; and

(g) such
other information relating to the financial condition, business, prospects, or corporate affairs of the Company as any Major Investor
may from time to time reasonably request; provided, however, that the Company shall not be obligated under this Section
3.1 to provide information (i) that the Company reasonably determines in good faith to be a trade secret or confidential information
(unless covered by an enforceable confidentiality agreement, in a form acceptable to the Company); or (ii) the disclosure of which would
adversely affect the attorney-client privilege between the Company and its counsel.

for any period, the Company has any subsidiary whose accounts are consolidated with those of the Company, then in respect of such period
the financial statements delivered pursuant to the foregoing sections shall be the consolidated and consolidating financial statements
of the Company and all such consolidated subsidiaries.

Notwithstanding
anything else in this Section 3.1 to the contrary, the Company may cease providing the information set forth in this Section
3.1 during the period starting with the date sixty (60) days before the Company’s good-faith estimate of the date of
filing of a registration statement if it reasonably concludes it must do so to comply with the SEC rules applicable to such
registration statement and related offering; provided that the Company’s covenants under this Section 3.1 shall
be reinstated at such time as the Company is no longer actively employing its commercially reasonable efforts to cause such
registration statement to become effective.

3.2 Inspection.
The Company shall permit each Major Investor, at such Major Investor’s expense, to visit and inspect the Company’s properties;
examine its books of account and records; and discuss the Company’s affairs, finances, and accounts with its officers, during normal
business hours of the Company as may be reasonably requested by the Major Investor; provided, however, that the Company
shall not be obligated pursuant to this Section 3.2 to provide access to any information that it reasonably and in good faith
considers to be a trade secret or confidential information (unless covered by an enforceable confidentiality agreement, in form acceptable
to the Company) or the disclosure of which would adversely affect the attorney-client privilege between the Company and its counsel.
Notwithstanding the foregoing or anything to the contrary contained in this Agreement, the Company acknowledges and agrees that the Relevant
Parties (as defined below) and other entities listed below (together the “Auditing Parties”) shall be allowed, during
normal business hours and subject to a reasonable notice period, to: (i) visit the sites, facilities, installations and works comprising
the Company; (ii) interview representatives of the Company; (iii) monitor the structure of the investment within and the management of
the Company; (iv) conduct such on-the-spot audits and checks as they may wish and review the Company’s books and records in relation
to the execution of Andera’s (as defined below) investment within the Company, it being agreed that such entities shall be authorized
to take copies of related documents to the extent permitted by the law (the “Inspection Rights”). Upon the occurrence
of a visit as referred to in the preceding sentence, the Company will provide the concerned Relevant Party with such documents that it
may reasonably require and that are in the Company’s possession that fall within the aforementioned scope. If such documents are
not in the Company’s possession, the Company will make reasonable efforts to obtain them provided that it does not incur any costs
in relation therewith. The Company further acknowledges that the EIF may be obligated to communicate information relating to Andera’s
investment within the Company, and generally to the Company, to any Relevant Party in accordance with the relevant mandatory provisions
of the laws of the European Union. The applicable Relevant Party or Auditing Party shall bear its own costs related to the Inspection
Rights, provided however, that if such party concludes that the Company is acting in breach of any material laws or binding regulations
applicable to it, the Company shall reimburse such party for all its costs and expenses related to the Inspection Rights. For the purposes
of this Section 3.2, “Relevant Parties” shall mean the European Court of Auditors, the European Commission,
the European Anti-Fraud Office and any other competent EU institution or body, as well as any persons designated by any of the foregoing;
and “Auditing Parties” shall mean the EIF, LfA Forderbank Bayern (“LfA”), KFW, the German Ministry
of Economic Affairs (Bundesministerium fur Wirtschaft and Technologie) and the German Federal Court of Auditors (Bundesrechnungshof)
(each either in person or by way of a duly authorized third party), and when so required by the relevant mandatory provisions of EU law,
the Relevant Parties.

3.3 Termination
of Information. The covenants set forth in Section 3.1 and Section 3.2 shall terminate and be of no further force or
effect (i) immediately before the consummation of the IPO, (ii) when the Company first becomes subject to the periodic reporting requirements
of Section 12(g) or 15(d) of the Exchange Act, or (iii) upon the closing of a Deemed Liquidation Event, as such term is defined in the
Certificate of Incorporation, whichever event occurs first; provided, that, with respect to clause (iii), the covenants
set forth in Section 3.1 shall only terminate if the consideration received by the Investors in such Deemed Liquidation Event
is in the form of cash and/or publicly traded securities or if the Investors receive financial information from the acquiring company
or other successor to the Company comparable to those set forth in Section 3.1.